Your Health Questions
Answered by Professionals

Yes, many insurance plans cover routine patient care costs for approved depression clinical trials, but they usually do not cover the experimental treatment or extra research-only tests, and coverage varies by insurer, plan type, funding, and state law. There are several factors to consider, so confirm specifics with the research coordinator and your insurer; see details below. If you are still depressed, medically approved next steps include medication adjustments, evidence-based therapy, FDA approved options like TMS, ECT, and esketamine, plus targeted lifestyle supports and diagnostic re-evaluation, with key risks, decision checklists, and timing guidance explained below.

If you are still depressed after at least two adequate antidepressant trials, a psychiatrist who specializes in treatment-resistant depression can guide proven next steps like optimized medication strategies and augmentation, esketamine, TMS, ECT, ketamine infusions, and targeted psychotherapies. There are several factors to consider. See below to understand how to confirm TRD, rule out look-alike conditions, find and vet the right specialist, prepare your treatment history, and know when to seek urgent help.

Precision medicine in psychiatry personalizes depression treatment using pharmacogenomic testing, careful symptom profiling, targeted labs for inflammation and nutrient deficiencies, and, when appropriate, options like TMS, ketamine or esketamine, always combined with evidence based therapy and lifestyle changes. Next steps often include reassessing the diagnosis, confirming adequate medication trials, considering genetic testing, screening for medical contributors, and discussing advanced treatments, with urgent care for any suicidal thoughts. There are several factors to consider; see below for the detailed roadmap, key caveats, and safety guidance that could change which steps are right for you.

There are several evidence-based options if depression persists; current research shows it involves brain connectivity, stress hormones, inflammation, and neuroplasticity, and highlights new choices beyond SSRIs such as TMS and ketamine or esketamine, with psychedelic-assisted therapy still under study and lifestyle changes remaining foundational. See below for complete details that can influence which path is right for you. Next steps include confirming the diagnosis, optimizing or switching medications, adding proven therapy, improving sleep, activity, diet, and alcohol use, and asking about advanced treatments, with urgent care needed for suicidal thoughts or severe decline. For a fuller picture and practical, step-by-step guidance, see below.

New, evidence-based options for bipolar depression include newer FDA-approved meds such as quetiapine, lurasidone, cariprazine, lumateperone, and olanzapine with fluoxetine, optimization of lithium or lamotrigine, rapid-acting ketamine or esketamine, and brain-based therapies like TMS and ECT, plus targeted psychotherapies and lifestyle resets. There are several factors to consider for safety and fit, including metabolic risks, mixed features, sleep and substance use, and coexisting medical issues; see below for key details that can shape your choice. Your next steps may include a focused medication review, asking about treatment-resistant options, medical screening, bipolar-specific therapy, and a crisis plan for urgent symptoms, with step-by-step guidance below.

Persistent depressive disorder is a long lasting, medically recognized depression that lingers for 2 or more years and can keep your brain feeling stuck due to shifts in serotonin, norepinephrine, and dopamine, chronic stress hormone changes, early adversity, genetics, and entrenched negative thinking. There are several factors to consider. See below for complete next steps on ruling out medical causes, choosing proven treatments like SSRIs SNRIs or bupropion plus CBT or CBASP, adding sleep and exercise routines, considering options like TMS or ketamine if standard care falls short, and seeking urgent help for suicidal thoughts.

Low dose ketamine IV infusions in a monitored clinical setting can offer rapid relief for treatment resistant depression, often using about 0.5 mg/kg over 40 minutes in a series of six treatments, with some patients moving to maintenance sessions. Candidacy, safety, and access vary, and key details about benefits, side effects, monitoring needs, costs, and how this differs from esketamine may shape your next steps; there are several factors to consider, so see below for the complete information.

The updated medical protocol uses 10,000 lux white light at midday, starting at 15 minutes daily and gradually increasing to 45 to 60 minutes while on a mood stabilizer; in studies, this reduced depressive symptoms and raised remission rates without increasing mania risk. Midday timing appears safer than morning because it supports circadian rhythms while protecting sleep. There are several factors to consider, including who should avoid it, how to monitor for early hypomanic signs, device setup, and how to coordinate with your clinician. See below for specifics that could change your next steps, especially if you have current hypomania or safety concerns like suicidal thoughts.

If you’re still depressed despite treatment, a psychiatry second opinion can confirm or refine your diagnosis, adjust medications and therapy, check for medical causes, and introduce options like TMS or esketamine; there are several factors to consider. See below to understand more. It is especially important if symptoms persist after 8 to 12 weeks, worsen, or feel mismatched to your diagnosis, and urgent care is needed for thoughts of self-harm; practical steps and signs to guide your next move are detailed below.

Still feeling depressed on bipolar-safe antidepressants often means the mood stabilizer is not fully optimized, symptoms are mixed or rapidly cycling, the antidepressant is worsening instability, or another condition like thyroid issues, anxiety, or ADHD is involved. There are several factors to consider; see below to understand more. Below you will find targeted next steps that can change outcomes, including optimizing mood stabilization first, using FDA-approved options for bipolar depression such as quetiapine, lurasidone, cariprazine, lumateperone, or the olanzapine fluoxetine combination, and when to consider ketamine or esketamine, ECT, TMS, and key sleep and medical checks.

If depression persists despite therapy or medications, exploring clinical trial eligibility can provide access to innovative treatments and intensive monitoring that are not yet widely available. There are several factors to consider, including specific inclusion criteria, informed consent and safety oversight, and how to work with your doctor to decide next steps and when urgent symptoms require immediate care. See complete details below.

If standard therapy and antidepressants have not helped, emerging options like ketamine or esketamine, TMS, psychedelic-assisted therapy in controlled settings, and other neuromodulation approaches can help some people with treatment-resistant depression by targeting different brain circuits. There are several factors to consider, including eligibility, safety and side effects, access and insurance, and confirming the right diagnosis and care plan; see below for how each option works, who benefits, and the specific next steps to discuss with your clinician.

There are several factors to consider when comparing microdosing and clinical trials; see below to understand more. Microdosing is largely unregulated with limited evidence, unpredictable dosing and purity, potential drug interactions, and legal risk, while clinical trials offer medical screening and supervision, standardized and pharmaceutical-grade treatments, safety monitoring, and often no cost; the details below also cover when urgent symptoms need immediate care and how to assess eligibility so you can choose the safest next step in your care.

New 2026 depression treatments can be your next medical step, especially for treatment resistant or severe symptoms, with options like next generation ketamine and other glutamate modulators, psychedelic-assisted therapy under supervision, faster and personalized TMS, inflammation or hormone-focused approaches, and AI-guided digital therapeutics. There are several factors to consider, including who is a candidate, required monitoring, access and cost, and how to combine these with therapy, so talk with your clinician and review the complete guidance below to choose the safest and most effective path for you.

New glutamate based antidepressants, led by ketamine and FDA approved esketamine, can deliver relief in hours to days for people who did not respond to SSRIs or SNRIs by rapidly modulating glutamate pathways and promoting brain plasticity. There are several factors to consider, including who is a candidate, medical supervision and side effects like dissociation and blood pressure spikes, and the pipeline of next generation oral or mGluR modulators and how to combine them with therapy or existing meds; see complete details below to guide your next steps with a clinician.

If your depression persists after standard treatments, medically supervised and regulated depression medication trials are a validated next step that can offer access to newer therapies, expert monitoring, and options tailored to treatment resistant depression. There are several factors to consider. See below to understand more, including eligibility, potential benefits and risks such as side effects or placebo assignment, how to talk with your doctor, and when to seek urgent help.

There are several factors to consider. New mental health research shows depression is more than a chemical imbalance, involving brain circuits, inflammation, sleep, chronic stress, trauma, hormones, genetics, and social connection, so personalized care is key. Next steps can include reassessing your diagnosis and medical contributors, combining or adjusting therapy and medications, aggressively treating sleep, supporting physical health and connection, and considering newer options like ketamine or esketamine, TMS, or ECT when appropriate; see the complete details below, including safety red flags and how to choose the right path.

Psilocybin therapy is a structured, medically supervised treatment that pairs one or a few doses with guided preparation and integration, and growing clinical research shows rapid, sometimes lasting relief for major and treatment-resistant depression by disrupting rigid brain patterns. There are several factors to consider, including careful screening, who should avoid it, and limited legal access; many more important details that could affect your next healthcare steps are explained below.

Rapid acting antidepressants like esketamine and medically supervised ketamine can deliver relief in hours to days for severe or treatment resistant depression by acting on the brain’s glutamate system, offering a faster option than standard antidepressants. There are several factors to consider, including eligibility, in clinic monitoring, side effects, and how these treatments fit into a broader care plan; see the important details below to guide your next steps and know when urgent care is needed.

If your depression has not improved with therapy, medication, or lifestyle changes, a mental health research study may be a practical next step, offering early access to innovative treatments, close medical monitoring, and structured, evidence-based care. Many studies also reduce or eliminate costs and allow you to help advance future treatments; there are several factors to consider, so see below to understand more. Safety is supported by ethical oversight and informed consent, but eligibility rules, potential side effects, visit schedules, and the chance of placebo mean you should review details with your clinician and seek urgent help now if you have suicidal thoughts; key questions and next-step guidance are outlined below.

Still depressed despite medication and therapy? Standard care can miss the mark because of individual biology, slow treatment adjustments, limited access, and partial response; roughly one-third of people do not fully respond to the first treatment. Clinical trials can provide closer monitoring and access to newer or faster acting options that target different pathways and may be more personalized. There are several factors to consider, and benefits, risks, and timing vary by person; see below for the complete answer and key details that could guide your next steps with your clinician.

If depression persists despite therapy or medication, fast-evolving psychiatry offers more personalized and rapid options, including pharmacogenomic-guided meds, TMS or ECT, ketamine or esketamine, digital and AI-supported tools, and whole-person care, with psychedelic-assisted therapy under study. There are several factors to consider, like confirming the diagnosis, working with a specialist in treatment-resistant depression, reviewing sleep, thyroid, and inflammation, understanding access and insurance, and knowing when to seek urgent help. See below for complete details that could change your next steps.

Still depressed despite treatment? The psychiatric drug pipeline offers new, often rapid-acting options beyond serotonin, including ketamine and esketamine, psychedelic-assisted therapy in trials, neurosteroids, and emerging anti-inflammatory and dopamine-targeted treatments that may help when first-line drugs do not. There are several factors to consider. See below for who might qualify, safety and supervision, insurance and access, and what to ask your doctor and about clinical trials, since these details can shape your next steps.

If your depression has not improved after several medications and therapy, vagus nerve stimulation is an FDA approved, medically proven option for adults with treatment resistant depression that uses a small implanted device to send gentle pulses to the vagus nerve and can provide gradual, long term improvement. There are several factors to consider. See below for details on candidacy after multiple failed treatments, the surgical and programming process, common side effects like hoarseness, how VNS compares with ECT, TMS, and ketamine, timelines for benefit, and when to seek urgent care.

For some people, persistent depression is linked to chronic brain inflammation that disrupts neurotransmitters, stress responses, and energy, especially when symptoms resist standard treatment and coexist with fatigue, brain fog, pain, gut issues, or autoimmune and metabolic problems. Discuss with your clinician a medical workup (CRP, thyroid, vitamin D, B12 and folate, blood sugar and insulin, autoimmune screening) and targeted steps like optimizing sleep, Mediterranean-style nutrition with omega-3s, regular exercise, and condition-specific treatments, and seek urgent help for any self-harm thoughts; there are several factors to consider, and key nuances that could change next steps are outlined below.

If depression persists despite therapy, medication, and lifestyle changes, brain stimulation options like TMS, ECT, and VNS can directly target disrupted mood circuits and are FDA-cleared or strongly evidence based for treatment-resistant depression. There are several factors to consider; see below for safety screening, candidacy, expected results and maintenance, emerging options, and when to seek urgent care, as these details can guide your next steps with your doctor.

If you remain depressed after trying antidepressants, you may be dealing with treatment resistant depression related to glutamate pathway issues, stress driven brain changes, medical or genetic factors, or misdiagnosis; there are several factors to consider, and the details below can shape your next steps. Spravato esketamine nasal spray is a clinic based, rapid acting option for eligible adults that is used with an oral antidepressant and requires evaluation, enrollment, monitored induction and maintenance visits, and integration with therapy and lifestyle care, with risks and urgent warning signs explained below.

If your depression is not improving after standard treatments, it may be treatment-resistant, reflecting issues like diagnosis, dosing, coexisting conditions, inflammation, or brain circuitry; there are several factors to consider, and you can see below to understand more. New clinical trial recruitment offers access to rapid-acting and glutamate-based medicines, brain stimulation, anti-inflammatory strategies, and personalized approaches with structured screening, consent, and close monitoring, so talk with your clinician about eligibility and the right next steps.

Still depressed after antidepressants? There are several factors to consider, including brain circuit differences, inflammation, genetics and metabolism, or a missed diagnosis, and there are newer options like ketamine or esketamine, TMS, ECT, psilocybin-assisted therapy, VNS, and augmentation strategies. See below for what qualifies as treatment resistant, how to pair therapy, sleep, exercise and nutrition with meds, and the exact next steps to discuss with your doctor, including when to seek urgent help.

There are several factors to consider. Up to 1 in 3 people with major depression do not fully respond to a first antidepressant because of brain circuit differences, mismatched medication targets, inadequate dose or duration, overlapping conditions or misdiagnosis, trauma, and genetic metabolism differences. Medically approved next steps include careful medication optimization or augmentation, interventional psychiatry such as TMS and esketamine, ECT, evidence-based psychotherapy, and targeted lifestyle support; see the complete guidance below for who each option fits, safety and monitoring details, and when urgent evaluation is needed, as these points can shape your next steps.